| Literature DB >> 33204286 |
Cheng Zhang1, Lidan Zhang1, Jian Lyu1, Yanming Xie1, Yuting Xie2.
Abstract
OBJECTIVE: Our aim was to analyze the influence of Yinzhihuang granules on serum liver enzymes in jaundice patients and to provide real-world evidence for the efficacy evaluation of Yinzhihuang granules in treating jaundice.Entities:
Year: 2020 PMID: 33204286 PMCID: PMC7661130 DOI: 10.1155/2020/3843752
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The demographic and clinical characteristics of the jaundice patients.
| Characteristic | Population |
|---|---|
| Gender | |
| Male | 2479 |
| Female | 1087 |
| Missing | 44 |
| Age | |
| ≤12 yr | 760 |
| 12–18 yr | 54 |
| 18–45 yr | 1029 |
| 45–65 yr | 1242 |
| 65–85 yr | 507 |
| >85 yr | 16 |
| Hospitalization time | |
| ≤3 d | 242 |
| 3–7 d | 491 |
| 7–14 d | 831 |
| 14–28 d | 1065 |
| Missing | 67 |
| Western medicine diagnosisa | |
| Neonatal hyperbilirubinemia | 238 |
| Pulmonary tuberculosis | 170 |
| Chronic active hepatitis B | 79 |
| TCM syndromeb | |
| Damp-heat brewing internally | 67 |
| Deficiency of both qi and blood | 32 |
| Yang qi deficiency | 32 |
| Single dose | |
| ≤6 g | 3337 |
| 6–12 g | 47 |
| 12–18 g | 16 |
| 18–30 g | 37 |
| 30–60 g | 23 |
| >60 g | 20 |
| Missing | 6 |
| Course of treatment | |
| ≤3 d | 1269 |
| 4–7 d | 567 |
| 8–14 d | 530 |
| 15–28 d | 432 |
| Missing | 649 |
| Combined use of drugsc | |
| TCM: Ganmao Qingre granules | 416 |
| TCM: Kuhuang injection | 382 |
| TCM: Bupleurum injection | 360 |
| Western medicine: glycyrrhizic acid | 1831 |
| Western medicine: thymosin | 1028 |
| Western medicine: dexamethasone | 592 |
a,b,cThe top three in population.
Description of premedication serum liver enzyme indicators (nonnormal distribution).
| Variable | Number of case ( | Median | Lower quartile | Interquartile range | Upper quartile | Minimum | Maximum |
|---|---|---|---|---|---|---|---|
| TBil ( | 952 | 79.00 | 35.50 | 169.80 | 205.30 | 12.00 | 609.60 |
| DBil ( | 1027 | 16.90 | 9.00 | 37.00 | 46.00 | 0.10 | 402.90 |
| IBil ( | 241 | 66.10 | 27.20 | 134.40 | 161.60 | 8.50 | 379.30 |
| ALT (U/L) | 596 | 25.00 | 13.00 | 50.50 | 63.50 | 4.00 | 3160.0 |
| AST (U/L) | 586 | 62.00 | 38.00 | 83.00 | 121.00 | 6.00 | 2232.0 |
| GGT (U/L) | 706 | 105.00 | 43.00 | 181.00 | 224.00 | 4.00 | 2487.0 |
| ALP (U/L) | 732 | 143.50 | 100.00 | 107.50 | 207.50 | 43.60 | 2098.0 |
The number of cases (n) counts the patients who had a premedication test.
Description of the postmedication serum liver enzyme indicators (nonnormal distribution).
| Variable | Number of case ( | Median | Lower quartile | Interquartile range | Upper quartile | Minimum | Maximum | |
|---|---|---|---|---|---|---|---|---|
| TBil ( | 549 | 69.10 | 28.20 | 146.20 | 174.40 | 5.70 | 766.60 | |
| DBil ( | 550 | 14.75 | 8.00 | 30.50 | 38.50 | 0.30 | 560.20 | |
| IBil ( | 62 | 43.55 | 19.80 | 72.90 | 92.70 | 10.10 | 289.90 | |
| ALT (U/L) | 245 | 27.00 | 14.00 | 57.00 | 71.00 | 3.00 | 3160.0 | |
| AST (U/L) | 225 | 29.00 | 35.00 | 82.00 | 117.00 | 15.00 | 13750.0 | |
| GGT (U/L) | 357 | 94.00 | 43.00 | 173.00 | 216.00 | 9.00 | 3645.00 | |
| ALP (U/L) | 349 | 124.00 | 91.00 | 97.00 | 188.00 | 15.00 | 1683.00 | |
The number of cases (n) counts the patients who had a postmedication test.
Figure 1TBil boxplot (n = 369).
Figure 2DBil boxplot (n = 392).
Figure 3IBil boxplot (n = 49).
Figure 4ALT boxplot (n = 166).
Figure 5AST boxplot (n = 158).
Figure 6GGT boxplot (n = 228).
Figure 7ALP boxplot (n = 231).
Changes of serum liver enzyme indicators after the medication (decrease/increase).
| Variable | Decrease/counts | Increase/counts | Invariance/counts | Total |
|---|---|---|---|---|
| TBil ( | 209 (56.64%) | 88 (23.85%) | 72 (19.51%) | 369 (100%) |
| DBil ( | 177 (45.15%) | 13 (35.20%) | 77 (19.64%) | 392 (100%) |
| IBil ( | 30 (61.22%) | 16 (32.65%) | 3 (6.12%) | 49 (100%) |
| ALT (U/L) | 78 (46.99%) | 60 (36.14%) | 28 (16.87%) | 166 (100%) |
| AST (U/L) | 84 (53.16%) | 54 (34.18%) | 20 (12.66%) | 158 (100%) |
| GGT (U/L) | 122 (53.51%) | 73 (32.02%) | 33 (14.47%) | 228 (100%) |
| ALP (U/L) | 119 (51.52%) | 79 (34.20%) | 33 (14.29) | 231 (100%) |
Classification of serum liver enzyme indicators after the medication (normal/abnormal).
| Variable | Normal/counts | Abnormal/counts | Total |
|---|---|---|---|
| TBil ( | 281 (76.15%) | 88 (23.85%) | 369 (100%) |
| DBil ( | 268 (68.37%) | 124 (31.63%) | 392 (100%) |
| IBil ( | 35 (71.43%) | 14 (28.57%) | 49 (100%) |
| ALT (U/L) | 136 (81.93%) | 30 (18.07%) | 166 (100%) |
| AST (U/L) | 114 (72.15%) | 44 (27.85%) | 158 (100%) |
| GGT (U/L) | 177 (77.63%) | 51 (22.37%) | 228 (100%) |
| ALP (U/L) | 183 (79.22%) | 48 (20.78%) | 231 (100%) |
Difference in the serum liver enzyme levels before and after the medication.
| Variable | Number of case ( | Premedication (mean ± SD) | Postmedication (mean ± SD) | Statistics ( |
|
|---|---|---|---|---|---|
| TBil ( | 369 | 126.46 ± 109.82 | 112.42 ± 109.64 | 9106.50 | ≤0.001 |
| DBil ( | 392 | 43.19 ± 62.70 | 46.96 ± 79.43 | 1422.50 | 0.3801 |
| IBil ( | 49 | 96.22 ± 82.22 | 63.03 ± 53.66 | 277.00 | 0.0017 |
| ALT (U/L) | 166 | 108.87 ± 295.46 | 91.76 ± 282.56 | 865.50 | 0.0656 |
| AST (U/L) | 158 | 135.55 ± 241.51 | 200.28 ± 986.27 | 1031.50 | 0.0278 |
| GGT (U/L) | 228 | 190.13 ± 250.46 | 182.61 ± 288.87 | 2872.50 | ≤0.001 |
| ALP (U/L) | 231 | 187.77 ± 163.00 | 186.43 ± 197.09 | 2656.50 | ≤0.001 |